|
|
|
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
Industry Events |
 |
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)
12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical
companies of manufacturing, primary and secondary packaging, purchasing,
and supply chain and procurement sectors, CMOs and CDMOs leaders, heads
from government and institution on 12-13, June, 2023 in Geneva,
Switzerland.
More info >> |
|
 |
News and Press Releases |
 |
NICE publishes guidance recommending Bayer’s Kerendia® (finerenone) as an option for treating adult patients with chronic kidney disease associated with type 2 diabetes
Reading, 23rd March 2023 – Today, the National Institute for Health and
Care Excellence (NICE) has published a new guidance (TA877) recommending
the use of finerenone (10mg and 20mg) by NHS England as an option for
treating chronic kidney disease (CKD) (stage 3 and 4 with albuminuria)
associated with type 2 diabetes in adults.1 Finerenone is recommended as
an add-on to optimised standard care, which should include, unless they
are unsuitable, the highest tolerated licensed doses of
angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor
blockers (ARBs), and sodium–glucose cotransporter-2 (SGLT2) inhibitors,
for people who have an estimated glomerular filtration rate (eGFR) of 25
ml/min/1.73 m2 or more.1
More info >> |
|
|
